FAQs on Asparaginase for ALL
FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia

Released: February 20, 2023

Expiration: February 19, 2024

Emily Curran
Emily Curran, MD
Daniel J. DeAngelo
Daniel J. DeAngelo, MD, PhD
Kjeld Schmiegelow
Kjeld Schmiegelow, MD, DMSci

Activity

Progress
1
Course Completed

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.

Topics discussed include:

  • - Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase
  • - Indirect methods for measuring asparaginase activity
  • - Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis
  • - Considerations for use of asparaginase in special populations (eg, high BMI, older age)